Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04695977
Title CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Checkmate Pharmaceuticals
Indications

melanoma

Therapies

Nivolumab

Nivolumab + Vidutolimod

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.